EnClear Therapies Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 18

EnClear Therapies General Information

Description

Developer of device-based therapies designed to treat neurological diseases. The company's neurology-focused device-based systems remove toxic proteins as therapies and provide closed-loop delivery and monitoring of cerebrospinal fluids (CSF), enabling doctors to halt the progression of the disease and extend the lives of patients with amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP).

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 65 Parker Street
  • Suite 3A
  • Newburyport, MA 01950
  • United States
+1 (978)
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 65 Parker Street
  • Suite 3A
  • Newburyport, MA 01950
  • United States
+1 (978)

EnClear Therapies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EnClear Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 03-Sep-2024 Completed Clinical Trials - General
5. Grant 03-Sep-2024 Completed Clinical Trials - General
4. Later Stage VC (Series 3) 01-Mar-2024 Completed Clinical Trials - General
3. Early Stage VC (Series A) 18-Feb-2020 Completed Clinical Trials - General
2. Early Stage VC (Series A2) 26-Mar-2019 $2M $2M Completed Product Development
1. Accelerator/Incubator Completed Product Development
To view EnClear Therapies’s complete valuation and funding history, request access »

EnClear Therapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-3
Seed-2
Seed-1
Series A-2 124,003 $0.000100 6% $17.28 $17.28 1x $6 3.35%
Series A-1 210,539 $0.000100 6% $45 $45 1x $14.9 5.97%
To view EnClear Therapies’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

EnClear Therapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of device-based therapies designed to treat neurological diseases. The company's neurology-focused device-base
Therapeutic Devices
Newburyport, MA
9 As of 2026

Cambridge, MA
 

Gosselies, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EnClear Therapies Competitors (2)

One of EnClear Therapies’s 2 competitors is QurAlis, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
QurAlis Venture Capital-Backed Cambridge, MA
OncoDNA Venture Capital-Backed Gosselies, Belgium
You’re viewing 2 of 2 competitors. Get the full list »

EnClear Therapies Patents

EnClear Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250360269-A1 Method and apparatus for determining patency for an intrathecal access site Pending 22-May-2024
WO-2025245323-A1 Method and apparatus for determining patency for an intrathecal access site Pending 22-May-2024
EP-4673192-A2 Csf therapeutic delivery system Pending 28-Feb-2023
US-20240285854-A1 Csf therapeutic delivery system Pending 28-Feb-2023
WO-2024182544-A2 Csf therapeutic delivery system Inactive 28-Feb-2023 A61M5/16877
To view EnClear Therapies’s complete patent history, request access »

EnClear Therapies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EnClear Therapies Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Founders Fund Venture Capital Minority
National Cancer Institute Government
National Institutes of Neurological Disorders and Stroke Government
The Brain Tumor Investment Fund Not-For-Profit Venture Capital Minority
The Sontag Foundation Limited Partner Minority
You’re viewing 5 of 18 investors. Get the full list »

EnClear Therapies FAQs

  • When was EnClear Therapies founded?

    EnClear Therapies was founded in 2018.

  • Where is EnClear Therapies headquartered?

    EnClear Therapies is headquartered in Newburyport, MA.

  • What is the size of EnClear Therapies?

    EnClear Therapies has 9 total employees.

  • What industry is EnClear Therapies in?

    EnClear Therapies’s primary industry is Therapeutic Devices.

  • Is EnClear Therapies a private or public company?

    EnClear Therapies is a Private company.

  • What is EnClear Therapies’s current revenue?

    The current revenue for EnClear Therapies is .

  • How much funding has EnClear Therapies raised over time?

    EnClear Therapies has raised $12.7M.

  • Who are EnClear Therapies’s investors?

    Founders Fund, National Cancer Institute, National Institutes of Neurological Disorders and Stroke, The Brain Tumor Investment Fund, and The Sontag Foundation are 5 of 18 investors who have invested in EnClear Therapies.

  • Who are EnClear Therapies’s competitors?

    QurAlis and OncoDNA are competitors of EnClear Therapies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process